» Articles » PMID: 35736462

MALDI Mass Spectrometry Imaging Highlights Specific Metabolome and Lipidome Profiles in Salivary Gland Tumor Tissues

Abstract

Salivary gland tumors are relatively uncommon neoplasms that represent less than 5% of head and neck tumors, and about 90% are in the parotid gland. The wide variety of histologies and tumor characteristics makes diagnosis and treatment challenging. In the present study, Matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI-MSI) was used to discriminate the pathological regions of patient-derived biopsies of parotid neoplasms by metabolomic and lipidomic profiles. Fresh frozen parotid tissues were analyzed by MALDI time-of-flight (TOF) MSI, both in positive and negative ionization modes, and additional MALDI-Fourier-transform ion cyclotron resonance (FT-ICR) MSI was carried out for metabolite annotation. MALDI-TOF-MSI spatial segmentation maps with different molecular signatures were compared with the histologic annotation. To maximize the information related to specific alterations between the pathological and healthy tissues, unsupervised (principal component analysis, PCA) and supervised (partial least squares-discriminant analysis, PLS-DA) multivariate analyses were performed presenting a 95.00% accuracy in cross-validation. Glycerophospholipids significantly increased in tumor tissues, while sphingomyelins and triacylglycerols, key players in the signaling pathway and energy production, were sensibly reduced. In addition, a significant increase of amino acids and nucleotide intermediates, consistent with the bioenergetics request of tumor cells, was observed. These results underline the potential of MALDI-MSI as a complementary diagnostic tool to improve the specificity of diagnosis and monitoring of pharmacological therapies.

Citing Articles

The Current State of Proteomics and Metabolomics for Inner Ear Health and Disease.

Khorrami M, Pastras C, Haynes P, Mirzaei M, Asadnia M Proteomes. 2024; 12(2).

PMID: 38921823 PMC: 11207525. DOI: 10.3390/proteomes12020017.


Recent Analytical Methodologies in Lipid Analysis.

Gerhardtova I, Jankech T, Majerova P, Piestansky J, Olesova D, Kovac A Int J Mol Sci. 2024; 25(4).

PMID: 38396926 PMC: 10889185. DOI: 10.3390/ijms25042249.


Advances in Imaging Mass Spectrometry for Biomedical and Clinical Research.

Djambazova K, van Ardenne J, Spraggins J Trends Analyt Chem. 2023; 169.

PMID: 38045023 PMC: 10688507. DOI: 10.1016/j.trac.2023.117344.


On-tissue dataset-dependent MALDI-TIMS-MS bioimaging.

Heuckeroth S, Behrens A, Wolf C, Futterer A, Nordhorn I, Kronenberg K Nat Commun. 2023; 14(1):7495.

PMID: 37980348 PMC: 10657435. DOI: 10.1038/s41467-023-43298-9.


Applications of spatially resolved omics in the field of endocrine tumors.

Hou Y, Gao Y, Guo S, Zhang Z, Chen R, Zhang X Front Endocrinol (Lausanne). 2023; 13:993081.

PMID: 36704039 PMC: 9873308. DOI: 10.3389/fendo.2022.993081.


References
1.
Dilillo M, Ait-Belkacem R, Esteve C, Pellegrini D, Nicolardi S, Costa M . Ultra-High Mass Resolution MALDI Imaging Mass Spectrometry of Proteins and Metabolites in a Mouse Model of Glioblastoma. Sci Rep. 2017; 7(1):603. PMC: 5429601. DOI: 10.1038/s41598-017-00703-w. View

2.
Fernandez L, Gomez de Cedron M, Ramirez de Molina A . Alterations of Lipid Metabolism in Cancer: Implications in Prognosis and Treatment. Front Oncol. 2020; 10:577420. PMC: 7655926. DOI: 10.3389/fonc.2020.577420. View

3.
Grimaldi M, Palisi A, Rossi G, Stillitano I, Faiella F, Montoro P . Saliva of patients affected by salivary gland tumour: An NMR metabolomics analysis. J Pharm Biomed Anal. 2018; 160:436-442. DOI: 10.1016/j.jpba.2018.08.015. View

4.
Sommella E, Carrizzo A, Merciai F, Di Sarno V, Carbone D, De Lucia M . Analysis of the metabolic switch induced by the spirulina peptide SP6 in high fat diet ApoE mice model: A direct infusion FT-ICR-MS based approach. J Pharm Biomed Anal. 2021; 195:113865. DOI: 10.1016/j.jpba.2020.113865. View

5.
Torresano L, Nuevo-Tapioles C, Santacatterina F, Cuezva J . Metabolic reprogramming and disease progression in cancer patients. Biochim Biophys Acta Mol Basis Dis. 2020; 1866(5):165721. DOI: 10.1016/j.bbadis.2020.165721. View